Biomarkers of Alcohol Consumption and Alcohol-induced Tissue Injury (SBIR [R43/R44])
The summary for the Biomarkers of Alcohol Consumption and Alcohol-induced Tissue Injury (SBIR [R43/R44]) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Biomarkers of Alcohol Consumption and Alcohol-induced Tissue Injury (SBIR [R43/R44]): Purpose. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to stimulate the discovery and development of biomarkers of alcohol consumption, biomarkers for early detection of alcohol-induced organ damage, and biomarkers of fetal alcohol exposure. Approaches using high throughput technologies leading to the discovery of biomarker signatures are encouraged. Proposals leading to rapid translation of candidates to marketable clinically useful biomarker assays are also encouraged. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with FOA RFA-AA-11-005, which solicits applications under the Small Business Technology Transfer (STTR) (R41) grant mechanism. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 2 to 4 projects awarded as a result of this announcement is $2M for fiscal year 2011. Future year amounts will depend on annual appropriations.
Federal Grant Title: | Biomarkers of Alcohol Consumption and Alcohol-induced Tissue Injury (SBIR [R43/R44]) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-AA-11-004 |
Type of Funding: | Grant |
CFDA Numbers: | 93.273 |
CFDA Descriptions: | Alcohol Research Programs |
Current Application Deadline: | Nov 02, 2010 |
Original Application Deadline: | Nov 02, 2010 |
Posted Date: | Aug 26, 2010 |
Creation Date: | Aug 27, 2010 |
Archive Date: | Dec 03, 2010 |
Total Program Funding: | $2,000,000 |
Maximum Federal Grant Award: | $200,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Limited Competition: Alcohol-associated Hepatitis Clinical Network Integrated Treatment C...
- • Limited Competition: Alcohol-associated Hepatitis Clinical Network Integrated Treatment C...
- • Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Dispari...
- • Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinica...
- • Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clin...
- • Mechanisms of Alcoholic Pancreatitis
- • Alcohol Abuse and Hiv/Aids in Resource-Poor Societies
- • Mechanisms of Alcohol-Induced Tissue Injury
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)